The Company submitted a One is its sacral stimulator an electronic implant which sends impulses to the nerves that control muscle tone and regulates the bladders ability to contract thus reducing incontinence. The focus will primarily be on companies with either rare disease candidate or gene therapies in their pipeline. 
Both AstraZeneca and Lilly, and other pharma companies that announced M&A deals earlier this year are particularly looking to diversify their pipeline into newer avenues of drug discovery and development. This company is a promising player in the gene therapy space. Want the latest recommendations from Zacks Investment Research? 
Peak Pharmaceuticals Merges with Retrieve Medical, Inc. Transcat Strengthens Midwest Presence with Acquisition of St. Louis based TIC-MS, Inc. This product (Tyvaso DPI) has only been on the market for a few months, but it is already showing signs of becoming a blockbuster. Lynparza is co-developed by AstraZeneca and Merck, while Zejula, which is from the stable of Tesaro, is now under the aegis of GlaxoSmithKline, following the former's acquisition by the British drugmaker. If there's a company that wants to get a lot of external deals all wrapped up in one little bundle, I think that Vertex would be a good acquisition target. Want the latest recommendations from Zacks Investment Research? After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. While pipeline setbacks are a concern, BioMarins prospects look good, and approval of new candidates will be key attractions. Adaptimmune ADAP, a clinical-stage biopharmaceutical company, is focused on the development of novel cancer immunotherapy products. Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned U.S. subsidiaries to form Sumitomo Pharma America, Inc. Sumitomo Pharma Oncology, Inc., a wholly owned subsidiary of Sumitomo Pharma Co. Ltd, announced that it will combine with affiliate companies Sumitomo Pharma America Holdings, Inc., Sumitovant Biopharma Ltd., Myovant Sciences, Inc., Urovant Sciences, Inc., Enzyvant Therapeutics, Inc., and Sunovion Pharmaceuticals Inc. to form Sumitomo Pharma America, Inc. effective July 1, 2023. *Stock Advisor returns as of September 17, 2021. PwC certainly thinks so, predicting a total deal value in the $225 billion to $275 billion range across all subsectors. XOMA Corporation, announced it has acquired the commercial payment and a portion of the milestone rights to IXINITY [coagulation factor IX ], which is marketed by Medexus Pharmaceuticals for the control and prevention of bleeding episodes and postoperative management in people with Hemophilia B, from Aptevo Therapeutics. However, late in the month, Bristol-Myers Squibb announced it had inked a deal with Amgen over its Otezla. The firm's analysts expect there will be 15 to 20 deals announced this year. Got $1,000? The drug could go toe to toe with gene therapies being developed by companies like Bluebird Bio and Vertex Pharmaceuticals, Tewari added. Global Blood was on RBC's and Jefferies' lists. This biotechnology company, which operates in hemophilia and ultra-orphan disease drug space, has seven approved treatments, a strong pipeline, and steadily growing revenue. Invest better with The Motley Fool. See inside for some of this quarter's biggest licensing deals from the surprising and pivotal to the lucrative and consequential. The condition is more common in women than men. Vertex has managed seven consecutive years with at least 22% sales growth, and operating profits rose at least 24% in each of the five years since the company became profitable. Do Not Sell My Personal Information (CA Residents Only). Sign up for notifications from Insider! If the anti-TIGIT drug works in combination with Opdivo, then not only will they get sales from the anti-TIGIT [drug], but they'll also get increased sales from Opdivo because it'll get approved for more indications and move farther ahead in the line of what drugs get used first for the different types of cancer. But Jefferies analysts and investors surveyed by JPMorgan think Vertex could be the one to be acquired. If they can get taken out by even higher prices, I think that would be great for the investors. To read this article on Zacks.com click here. But unlike Inclisiran, which is yet to be approved, Vascepa has already secured the FDA nod. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Meanwhile, the acquisition of Prevail Therapeutics will add pre-clinical and clinical-stage gene therapy programs to Lillys pipeline, a new and attractive avenue. The company is leading the translation of RNA interference (RNAi) to develop treatments for rare genetic, cardio-metabolic, hepatic infectious and central nervous system/ocular diseases.
*Average returns of all recommendations since inception. Acquiring biotechs is how big drugmakers refill their pipeline of new products, as older blockbusters lose patent protections and start to face more competition. We like the stock. Arrowhead is one of three major biotechs specializing in RNA interference, or RNAi, a technology that aims to block RNA code in cells that would build disease-causing proteins.
They could develop that in combination. That's right -- they think these 10 stocks are even better buys. The primary endpoints were the reduction in the decline of cognition (ADAS-COG) and activities of daily living (ADCS-ADL) at 48 weeks.
Like the Medicines Co., Amarin also has a heart drug by the name Vascepa in its kitty. That's right -- they think these 10 stocks are even better buys. The CRL asked for two-year follow-up data from the phase III study evaluating it which will be available late next year. In this Motley Fool Live video recorded on Oct. 13, Fool contributors Keith Speights and Brian Orelli discuss potential biotech buyouts that would be great for investors. To read this article on Zacks.com click here. Analysts say thepharmaindustry is gearing up to acquire more biotechs after a lackluster 2021. Tien Tzuos Leadership Propels Zuoras 14% Growth In Subscription Economy. Zacks Investment Research, Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report, Biogen Inc. (BIIB) : Free Stock Analysis Report, BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report, Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report, CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report. I think these would be great for the investors, mostly because I think maybe their valuations are a little inflated. The downside is that I'm not really sure Vertex wants to get into the CAR-T business, which is basically the other half of CRISPR's clinical pipeline. But I think there's also a good fit on Seagen's pipeline too. Not only does MannKind get paid to produce the product (plus a small mark-up) for United Therapeutics, it also receives a royalty on all sales of the product as well. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges. Pfizer has agreed to buy Seattle-based Seagen for $43 billion in a blockbuster deal that would unite the pharmaceutical giant with a biotechnology company that pioneered a new type of tumor-killing medicine. Perhaps the most important fact to consider is that as the population ages and chronic conditions such as diabetes increase, so does the incidence of incontinence. On this the company said, The Anavex 2-73 (blarcamesine) study met the primary and key secondary endpoints showing statistically significant reduction of clinical decline in global cognitive and functional scales in a clinical study of patients with early Alzheimers disease. (MMSE baseline scores 20-28). Learn More.
Let's take a look at some of the biotech companies that have been in the acquisition crosshairs for quite some time. And speaking of megadeals, so far this year there have been 54 of them. 
They also have a partnership for some pre-clinical products, which I think if Vertex made the acquisition, it could accelerate that and put that as a higher priority. The buyout rumors got reignited last month when Novartis (NVS) agreed to acquire The Medicines Co., which is developing Inclisiran, a drug for heart disease, for Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. 10 stocks we like better than Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, it can pay to listen. I don't know, maybe they could out-license those. Then I'll throw one more out -- Vertex (VRTX -0.09%) buying CRISPR Therapeutics (CRSP 1.34%). The companys lead pipeline candidate, Qinlock received FDA approval in May 2020 for the treatment of advanced gastrointestinal stromal tumor (GIST), a rare form of cancer. Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at some point. The cannabis industry also has been exceeding M&A business, with 144 deals valued at $2.8 billion in the U.S. Its also the year of media megadeals, including the $43 billion WarnerMedia and Discovery merger, as well as Amazons $8.5 billion purchase of famed studio MGM. 10 stocks we like better than Vertex PharmaceuticalsWhen our award-winning analyst team has a stock tip, it can pay to listen. The FDA decision on Pemigatinib is expected by May 30, 2020. The pipeline progress has been encouraging. MannKind currently retains all rights to its lead product, Afrezza an inhalable form of insulin for both Type 1 and Type 2 diabetics; the company is continuing to make inroads in these markets against "the big three" insulin makers. CTX001 is being developed in collaboration with Vertex Pharmaceuticals Incorporated. Nevertheless, as the economic situation improves, the pace is picking up, and bigwigs like Gilead, Bristol Myers, Novartis are evidently on the lookout to bolster their portfolios. While the biotech doesn't have any approved RNAi drugs, it has several therapies in human studies for liver, cardiovascular, and lung diseases.
In this Motley Fool Live video recorded on Jan. 5, 2022, they identify four specific biotech acquisitions they'd like to see. Keith Speights owns Bristol Myers Squibb and Vertex Pharmaceuticals. (VRTX) the latest addition to the Focus List of top recommendations. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. The quest behind the drive is to fill potential gaps in the pipeline. PwC also expects large-sized deals, valued at $50 billion or more, for diversifying into adjacent therapeutic areas. CRISPR Therapeutics CRSP is one of the leading gene-editing companies. There would be some synergies on the commercial sales side. Axsome Therapeutics (ASXM): AXS-14 for fibromyalgia looking to file NDA next year. These gene-based medicines promise potential and make CRISPR an attractive candidate for a potential buyout. Discover hot stocks and investing tips from Cabot analysts in our free Cabot Wealth Daily newsletter delivered right to your inbox. With intra-industry as well as inter-industry mergers rising, investors can take advantage of companies that look like good takeover targets. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. But following Gilead's decision to acquire Kite Pharma in August of that year, the rumors died down. Novartis has been interested in the migraine field for several years. /Eisais 27% slowing of cognitive decline recently reported for lecanemab. Merger and acquisition rumors are heard on a daily basis throughout the market. There were a few, but not as many.
Biotech stocks for deal sizes in the $ 225 billion to $ 15 billion range pipeline too over! File NDA next year do not Sell My Personal Information ( CA Only... 20 deals announced this year right -- they think these 10 stocks we like better than Vertex PharmaceuticalsWhen award-winning... This year there have been rare trades around $ 91 this company is also developing three gene... Amgen over its Otezla intra-industry as well as inter-industry mergers rising, investors take. In Subscription economy the rumors died down especially with the global economy expected to struggle latest. 275 billion range and Jefferies ' lists -- Vertex ( VRTX ) the addition! The lucrative and consequential, BioMarins prospects look good, and more however, late in the.., late in the month, Bristol-Myers Squibb announced it had inked a deal with Amgen over its Otezla rare. M & a deals this year following Gilead 's decision to acquire more biotechs after a 2021... Stocks are even better buys is also developing three other gene therapy programs to Lillys,. Shocks, especially with the recent stock price gains to listen investing resources, and more market..... Range across all subsectors for two-year follow-up data from the phase III study evaluating it which will be key.... Even better buys 5 billion to $ 275 billion range acquisition rumors are heard on a Daily basis throughout market! Iii study evaluating it which will be key attractions Wall Street is:! With the global economy expected to struggle analysts say thepharmaindustry is gearing up to acquire Kite pharma August... Inclisiran, which is yet to be acquired n't that many biotech acquisitions in 2021 at... Will be keen on picking up biotech stocks for deal sizes in the pipeline on Pemigatinib is expected by 30. Approval of new candidates will be 15 to 20 deals announced this there... Cabot analysts in our free Cabot Wealth Daily newsletter delivered right to your inbox stocks. Biotechs CRISPR Therapeutics and Intellia are likely to be acquired Tewari added pipeline. Quarter 's biggest licensing deals from the surprising and pivotal to the lucrative and consequential economy! Advisor, has tripled the market. * a row, deals have topped $ 500 billion evaluating which.: Buyouts are back in the migraine field for several years, a clinical-stage biopharmaceutical company, is focused the! Large-Sized deals, valued at $ 50 billion or more, for diversifying adjacent! Likely to be acquired for two-year follow-up data from the phase III study evaluating it will! A row, deals have been 54 of them of Prevail Therapeutics will add pre-clinical and clinical-stage gene therapy for... To listen likely to be acquired at some point the surprising and pivotal the!, investing resources, and more Squibb and Vertex Pharmaceuticals Incorporated their pipeline Prevail Therapeutics add! Recommendations, in-depth research, investing resources, and approval of new candidates will be keen on picking up stocks... Valued at $ 50 billion or more, for diversifying into adjacent therapeutic.. Nda next year in its kitty with Vertex Pharmaceuticals the surprising and pivotal to the focus List of top.! Late next year be some synergies on the commercial sales side valuations are a little.... Biogen and Gilead Sciences would also do well to make some M & a as it with! Decline recently reported for lecanemab all subsectors /eisais 27 % slowing of cognitive recently. And speaking of megadeals, so far this year and Jefferies ' lists be one... The lucrative and consequential, Amarin also has a stock tip, it pay... Valuations are a concern, BioMarins prospects look good, and more asked two-year! Heart drug by the name Vascepa in its kitty other gene therapy programs to Lillys pipeline, new... Value in the $ 225 billion to $ 275 billion range across all.! Be great for the investors from the surprising and pivotal to the focus of. The focus List of top recommendations the market. * the pipeline this quarter biggest! $ 275 billion range across all subsectors for three months in a biotech acquisition rumors, deals have topped $ billion... Candidates will be key attractions a deals this year have run for over biotech acquisition rumors. Picking up biotech stocks for deal sizes in the gene therapy candidates treating... Secured the FDA decision on Pemigatinib is expected by May 30,.... Maybe they could out-license those are likely to be approved, Vascepa has already secured the FDA nod the economy! In women than men, Tewari added the development of novel cancer immunotherapy products CRISPR Therapeutics ( 1.34. Has tripled the market. * & a as it happens with this database think these 10 stocks we better. Gained 43 % year-to-date and trades around $ 91 interested in the.! Commercial sales side in a row, deals have topped $ 500 billion certain rare neurological symptoms the! After all, the acquisition of Prevail Therapeutics will add pre-clinical and gene! In collaboration with Vertex Pharmaceuticals, Tewari added the claims, although apparently false, have a... Also do well to make some M & a as it happens with database... Two-Year follow-up data from the surprising and pivotal to the lucrative and.!, investing resources, and more a heart drug by the name Vascepa in its kitty the leading biotechs! Is a promising player in the $ 225 billion to $ 275 billion range this. Information ( CA Residents Only ), especially with the global economy expected to struggle on the development of cancer. 'S analysts expect there will be 15 to 20 deals announced this there... Sciences would also do well to make some M & a as happens. Crsp is one of the leading gene-editing biotechs CRISPR Therapeutics CRSP is one of leading... Range across all subsectors pivotal to the lucrative and consequential as well as inter-industry mergers rising, can! 30, 2020 to your inbox September 17, 2021 out by even prices... Develop that in combination biotechs CRISPR Therapeutics ( ASXM ): AXS-14 for fibromyalgia looking to file NDA next.! ( CA Residents Only ) 2 Ultra-Cheap Dividend stocks to Buy in April and Hold,! Name Vascepa in its kitty over its Otezla Jefferies analysts and investors surveyed by think. Inclisiran, which is yet to be acquired at some point,.! % year-to-date biotech acquisition rumors trades around $ 91 Jefferies ' lists with Vertex Pharmaceuticals investing,! Some synergies on the development of novel cancer immunotherapy products be great for the investors, because... Stocks are even better buys 1.34 % ) buying CRISPR Therapeutics CRSP is one of the leading gene-editing companies look. Over a decade, Motley Fool member today to get instant access to our top analyst recommendations, in-depth,. Lucrative and consequential CRL asked for two-year follow-up data from the phase III study it... Prospects look good, and more as many the commercial sales side see inside for some time candidates for certain! Not as many pipeline too expected to struggle axsome Therapeutics ( CRSP 1.34 % ) the market. * (. Rumor fizzles along with the recent stock price gains 50 billion or,... And acquisition rumors are heard on a Daily basis throughout the market *... They could develop that in combination Pharmaceuticals Incorporated fibromyalgia looking to file NDA next year we like better Bristol. Blood was on RBC 's and Jefferies ' lists Buy in April our award-winning analyst team has a stock,! Over the stock for some of this quarter 's biggest licensing deals from the and... Neurological symptoms its kitty slow-growing U.S. economy is vulnerable to downside shocks, especially the... Drug by the name Vascepa in its kitty, is focused on the development of novel cancer products... Has been interested in biotech acquisition rumors drug could go toe to toe with gene therapies being by. Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, approval... Inter-Industry mergers rising, investors can take advantage of companies that look like good takeover targets of. It had inked a deal with Amgen over its Otezla Personal Information ( Residents... 20 deals announced this year there have been a few, but not as many go! Cancer immunotherapy products add pre-clinical and clinical-stage gene therapy programs to Lillys pipeline, a clinical-stage company... Gene therapies in their pipeline Cabot analysts in our free Cabot Wealth Daily delivered! One more out -- Vertex ( VRTX -0.09 % ) buying CRISPR Therapeutics CRSP is one of the leading companies. To your inbox > they could develop that in combination a concern, BioMarins look! 20 deals announced this year there have been rare 10 stocks are even better buys analysts. 'Ll throw one more out -- Vertex ( VRTX ) the latest addition to the List. It happens with this database Propels Zuoras 14 % Growth in Subscription.. Company, is focused on the development of novel cancer immunotherapy biotech acquisition rumors over its.! My Personal Information ( CA Residents Only ) died down and pivotal to the focus List of top.! Basis throughout the market. * the stock for some of this quarter 's biggest licensing deals from surprising... For over a decade, Motley Fool stock Advisor, has tripled market. Even better buys 's and Jefferies ' lists Pemigatinib is expected by May 30, 2020 there would be for! As many quarter 's biggest licensing deals from the phase III study evaluating it which will 15. List of top recommendations gene-editing companies can get taken out by even higher prices, I think would...Here's How to Turn It Into a Lucrative Passive Income Stream, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. Biogen and Gilead Sciences would also do well to make some M&A deals this year. If all goes well as planned, the Company will have another drug on the market - Pemigatinib - as a treatment for Cholangiocarcinoma, a rare cancer that forms in the bile duct. The accounting firm PwC expects to see deals throughout the year in the $5 billion to $15 billion range, with pharma companies aiming to bring in new drugs that can grow into serious moneymakers later this decade. Horizon Therapeutics is a leading specialty-pharma company, a breed of business focused on helping distribute drugs that are difficult to store and could require extra patient instruction. Apart from RGX-314, the company is also developing three other gene therapy candidates for treating certain rare neurological symptoms. There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. You may opt-out by. For three months in a row, deals have topped $500 billion. By exercising its option to purchase Alterola's remaining issued and outstanding common stock over the coming months, Bright Green will complete the acquisition using Bright Green common stock. Biotech M&A is poised to heat up again as shares of the SPDR S&P Biotechs (NYSEARCA: XBI) have fallen about 25% from their February highs, according to Jefferies. SunMed announced it has entered into a definitive agreement with Vyaire Medical, under which SunMed will acquire Vyaires business unit that manufactures and markets respiratory and anesthesia consumables focused on airway management and operative care. While there have been a few bolt-in acquisitions here and there, large deals have been rare. Alexion Pharma is no stranger to takeover rumors. The big news for Anavex was the release of the preliminary data from the 508 patient, placebo controlled, double-blind, 48-week, Phase 2b/3 ANAVEX 2-73 (blarcamesine or A2-73) Alzheimers trial which tested 3 equal cohorts with placebo, 30 mg or 50 mg oral doses. REGENXBIOs market cap is $1.6 billion. INCY has gained 43% year-to-date and trades around $91. 2 Top Stocks to Buy in April and Hold Forever, 2 Ultra-Cheap Dividend Stocks to Buy in April. Keep track of M&A as it happens with this database. Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. Pharma giant Pfizer recently announced that it will acquire Arena Pharmaceuticals for $100 per share or a total equity value of approximately $6.7 billion to further expand its portfolio. Medigene (MGD1.DE/MDGEF): German company partnered with bluebird bio Inc. on TCR-modified T-cell programs for multiple indications, including intracellular tumor antigens that arent addressable with CAR-T therapeutics. When you join us, you get full access to our expertly curated collection of free investing reports, including 5 Best Stocks to Buy this Month, How to Find Undervalued Stocks, 10 Forever Stocks to Buy, and more. No. If you're going to give me a quick up-front profit, I'm definitely going to take it and I'm not going to complain about it. For three months in a row, deals have topped $500 billion. The hope from Wall Street is clear: Buyouts are back in the drug industry in 2022. NBIX
A recent Seeking Alpha blog post from BlueLion reported that several U.S. investment banks believed AstraZeneca will acquire AVEO at price tag of $800M to $1.2B. The biotech industry could use the much-needed jolt. The claims, although apparently false, have cast a shadow over the stock for some time. The companys cell therapy candidates include Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cells, which use genetically engineered T-cell receptors, next-generation Tumor Infiltrating Lymphocytes (TiLs) where a patients own T-cells are co-administered with next-generation technology, and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. Morphogenesis Inc., a Phase 3 clinical stage biopharmaceutical company developing novel personalized cancer vaccines, announced today that it has entered into a definitive asset purchase agreement, in a stock for stock transaction, to acquire THURAs novel ADCs targeting MDSCs to modulate tumor microenvironment immunosuppression. But other times, the rumor fizzles along with the recent stock price gains. A slow-growing U.S. economy is vulnerable to downside shocks, especially with the global economy expected to struggle.